-Phase III trial enrolled a total of 480 patients with moderate to severe acne-Topline results expected in the second quarter 2025 This Phase III clinical trial is a randomized, double-blind, ...
SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and ...
Acne is one of the most common skin conditions seen in general practice. Acne vulgaris – the most prevalent form – affects more than 80% of teenagers and young adults (in some countries, it may be as ...
HANGZHOU, China, Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III clinical trial of ASC40 (denifanstat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results